{"id":"846aefe8-aa1d-4876-9581-975da117ab86","name":"MMI DMS LINKDOCUMENTS","timestamp":1447676759354,"order":["a1c0357c-0fc8-86a7-8a19-51c9405ce608","1924e4c1-17d8-8dbf-28a1-a22d0883a6e8","2a0726ed-9366-4489-116b-d0d5fe505fd3","24a1dd8b-3dcd-d909-c8de-3f192a0163ca","38098f2a-0f76-1017-3823-b57792935f16","07c7dbab-279d-2fe5-3d4c-2bd52463c099","83e57996-66bd-f4a9-72e1-25fda0511341"],"requests":[{"collectionId":"846aefe8-aa1d-4876-9581-975da117ab86","id":"07c7dbab-279d-2fe5-3d4c-2bd52463c099","name":"POST Document : 400 Bad Request","description":"No title will trigger bad request.","url":"http://localhost:8080/cms/linkdocuments/comments","method":"POST","headers":"","data":[{"key":"title","value":"","type":"text"},{"key":"products","value":"Temodal®, MSD Sharp & Dohme GmbH|TEMOZO-cell, cell pharm GmbH|Temozolomid HEXAL, Hexal AG|Temozolomid Hospira, Hospira Deutschland GmbH|Temozolomid-ratiopharm, ratiopharm GmbH|Temozolomid ribosepharm, Hikma Pharma GmbH|Temozolomid TEVA, TEVA GmbH|Temomedac, medac GmbH","type":"text"},{"key":"ingredients","value":"ing1|ing2|ing3","type":"text"},{"key":"companies","value":"MSD Sharp & Dohme GmbH|cell pharm GmbH|Hexal AG","type":"text"},{"key":"articledate","value":"06.11.2015","type":"text"},{"key":"description","value":"Die Hersteller Temozolomid-haltiger Arzneimittel  informieren in diesem Rote-Hand-Briefüber Fälle von Leberschäden, einschließlich letalem Leberversagen bei Patienten, die mit Temozolomid behandelt wurden. Deshalb  gelten ab sofort spezielle Empfehlungen zur Überwachung der Leberfunktion: -Die Leberwerte sollen vor der Behandlung und nach jedem Behandlungszyklus bestimmt werden. -Bei Patienten mit einem 42-tägigen Zyklus sollen die Werte auch in der Mitte des Behandlungszyklus bestimmt werden. -Bei abnormen Leberwerten ist das Nutzen-Risiko-Verhältnis vor und während der Behandlung sorgfältig abzuwägen und ggf. nicht begonnen oder abgebrochen werden.","type":"text"},{"key":"originalfile","value":"Rote-Hand-Brief zu Temozolomid.pdf","type":"text"},{"key":"sources","value":"Rote Hande Magazine|AWFS Magazine|Hexal AG","type":"text"},{"key":"friendlyurl","value":"http://www.gelbe-liste.de/c/document_library/get_file?uuid=319cf68f-6ebd-4c47-b533-f1786cc029b3&groupId=84530","type":"text"},{"key":"htmltitel","value":"not known html title","type":"text"},{"key":"keywords","value":"Rote Hande|Temozolomid|Hexal","type":"text"},{"key":"rights","value":"all","type":"text"}],"dataMode":"urlencoded","timestamp":0,"version":2,"time":1447676902542},{"collectionId":"846aefe8-aa1d-4876-9581-975da117ab86","id":"1924e4c1-17d8-8dbf-28a1-a22d0883a6e8","name":"GetDocument : JSON","description":"","url":"http://localhost:8080/dms/rest/linkdocuments/456","method":"GET","headers":"Accept: application/json\n","data":"{\n    \"authors\": [],\n    \"bodyPictures\": [],\n    \"friendlyUrl\": \"http://localhost:8080/dms/rest/articles/456\",\n    \"htmlTitle\": \"Article Two NOW updated\",\n    \"relations\": [],\n    \"rights\": [],\n    \"searchable\": false,\n    \"version\": 0\n}","dataMode":"raw","timestamp":0,"version":2},{"collectionId":"846aefe8-aa1d-4876-9581-975da117ab86","id":"24a1dd8b-3dcd-d909-c8de-3f192a0163ca","name":"POST Document : 201 Created","description":"We are expecting the REST 201 \"CREATED\" STANDARD HTTP code.","url":"http://localhost:8080/dms/rest/linkdocuments","method":"POST","headers":"Accept: application/json\n","data":[{"key":"title","value":"Title Goes here","type":"text"},{"key":"products","value":"Temodal®, MSD Sharp & Dohme GmbH|TEMOZO-cell, cell pharm GmbH|Temozolomid HEXAL, Hexal AG|Temozolomid Hospira, Hospira Deutschland GmbH|Temozolomid-ratiopharm, ratiopharm GmbH|Temozolomid ribosepharm, Hikma Pharma GmbH|Temozolomid TEVA, TEVA GmbH|Temomedac, medac GmbH","type":"text"},{"key":"ingredients","value":"ing1|ing2|ing3","type":"text"},{"key":"companies","value":"MSD Sharp & Dohme GmbH|cell pharm GmbH|Hexal AG","type":"text"},{"key":"articledate","value":"06.11.2015","type":"text"},{"key":"description","value":"Die Hersteller Temozolomid-haltiger Arzneimittel  informieren in diesem Rote-Hand-Briefüber Fälle von Leberschäden, einschließlich letalem Leberversagen bei Patienten, die mit Temozolomid behandelt wurden. Deshalb  gelten ab sofort spezielle Empfehlungen zur Überwachung der Leberfunktion: -Die Leberwerte sollen vor der Behandlung und nach jedem Behandlungszyklus bestimmt werden. -Bei Patienten mit einem 42-tägigen Zyklus sollen die Werte auch in der Mitte des Behandlungszyklus bestimmt werden. -Bei abnormen Leberwerten ist das Nutzen-Risiko-Verhältnis vor und während der Behandlung sorgfältig abzuwägen und ggf. nicht begonnen oder abgebrochen werden.","type":"text"},{"key":"originalfile","value":"Rote-Hand-Brief zu Temozolomid.pdf","type":"text"},{"key":"sources","value":"Rote Hande Magazine|AWFS Magazine|Hexal AG","type":"text"},{"key":"friendlyurl","value":"http://www.gelbe-liste.de/c/document_library/get_file?uuid=319cf68f-6ebd-4c47-b533-f1786cc029b3&groupId=84530","type":"text"},{"key":"htmltitel","value":"not known html title","type":"text"},{"key":"keywords","value":"Rote Hande|Temozolomid|Hexal","type":"text"},{"key":"rights","value":"all","type":"text"}],"dataMode":"urlencoded","timestamp":0,"version":2},{"collectionId":"846aefe8-aa1d-4876-9581-975da117ab86","id":"2a0726ed-9366-4489-116b-d0d5fe505fd3","name":"updateDocument : 200 OK","description":"","url":"http://localhost:8080/dms/rest/linkdocuments/456","method":"PUT","headers":"Accept: application/json\nContent-Type: application/json\n","data":"{\n    \"created\": \"2015-11-11T12:57:25.733+01:00\",\n    \"id\": 45576,\n    \"name\": \"New Title for 456: at 13:01\"\n}","dataMode":"raw","timestamp":0,"version":2},{"collectionId":"846aefe8-aa1d-4876-9581-975da117ab86","id":"38098f2a-0f76-1017-3823-b57792935f16","name":"deleteDocument : 202 Accepted","description":"","url":"http://localhost:8080/dms/rest/linkdocuments/456","method":"DELETE","headers":"Accept: application/json\n","data":"","dataMode":"raw","timestamp":0,"version":2},{"collectionId":"846aefe8-aa1d-4876-9581-975da117ab86","id":"83e57996-66bd-f4a9-72e1-25fda0511341","name":"Get Document : 500 DataNotFoundException","description":"","url":"http://localhost:8080/dms/rest/linkdocuments/4561","method":"GET","headers":"Accept: application/json\n","data":"","dataMode":"raw","timestamp":0,"version":2},{"collectionId":"846aefe8-aa1d-4876-9581-975da117ab86","id":"a1c0357c-0fc8-86a7-8a19-51c9405ce608","name":"Get Documents","description":"","url":"http://localhost:8080/dms/rest/linkdocuments?offset=30&limit=15","method":"GET","headers":"Accept: application/json\n","data":"{\n    \"created\": \"2015-11-11T12:57:25.733+01:00\",\n    \"id\": 45576,\n    \"name\": \"New Title for 456: at 13:01\"\n}","dataMode":"raw","timestamp":0,"version":2}]}